Bearish investors decided to classify Hims & Hers Health (HIMS) as an obesity drug supplier. HIMS stock lost 9.6% on Thursday after the U.S. Food and Drug Administration said that GLP-1, made by Eli ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Spirit Airlines considering bankruptcy filing - WSJ. Port strike ends as dockworkers said to agree on tentative deal with 62% ...

S hares of Hims & Hers (NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's (NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impac ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...

Hims & Hers offers a comprehensive weight loss solution personalized for individuals which may include compounded GLP-1 injections or oral weight loss medication kits as deemed appropriate by the ...